Marks Group Wealth Management Inc Increases Position in argenex SE $ARGX

Marks Group Wealth Management Inc boosted its position in argenex SE (NASDAQ:ARGX) by 24.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,523 shares of the company’s stock after acquiring an additional 299 shares during the period. Marks Group Wealth Management Inc’s holdings in argenex were worth $840,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Goldman Sachs Group Inc. grew its position in shares of argenex by 14.8% in the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after purchasing an additional 21,805 shares during the period. Amundi boosted its stake in argenex by 8.1% in the 1st quarter. Amundi now owns 6,351 shares of the company’s stock worth $3,747,000 after buying an additional 478 shares during the last quarter. Voya Investment Management LLC grew its holdings in argenex by 5.2% in the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock valued at $8,822,000 after buying an additional 735 shares during the period. Wealth Management Associates Inc. acquired a new position in shares of argenex during the 1st quarter valued at about $268,000. Finally, Royal Bank of Canada lifted its holdings in shares of argenex by 0.9% during the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after acquiring an additional 353 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

argenex stock opened at $787.94 on Tuesday. The firm has a market capitalization of $48.22 billion, a PE ratio of 40.41, a price-to-earnings-growth ratio of 0.87 and a beta of 0.46. argenex SE has a one year low of $510.05 and a one year high of $803.74. The stock’s 50 day moving average price is $706.83 and its 200 day moving average price is $622.35.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The company had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. On average, analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on ARGX shares. Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a research report on Thursday, September 11th. Bank of America upped their price objective on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Stifel Nicolaus set a $882.00 target price on argenex in a research report on Thursday, September 18th. HC Wainwright boosted their price target on argenex from $720.00 to $774.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. lifted their price objective on argenex from $775.00 to $830.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $802.90.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.